Short-term dual antiplatelet therapy for 1 to 3 months followed by potent P2Y12 inhibitor monotherapy reduces major bleeding without increasing ischemic events compared to 12-month DAPT in patients with acute coronary syndrome.
Does short-term DAPT followed by potent P2Y12 inhibitor monotherapy reduce major bleeding without increasing ischemic events in patients with ACS undergoing PCI?
Short-term DAPT (1-3 months) followed by potent P2Y12 inhibitor monotherapy reduces bleeding risk without increasing ischemic risk compared to standard 12-month DAPT in ACS patients undergoing PCI.
For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention, 12 months of dual antiplatelet therapy (DAPT) comprising aspirin and a P2Y 12 inhibitor is currently recommended as the standard treatment.However, several studies have suggested that the maintenance of DAPT for up to 12 months increases the risk of bleeding, which can be related to comorbidities and mortalities after bleeding events.Therefore, recent randomized clinical trials have indicated that short-term DAPT for 1 to 3 months followed by P2Y 12 inhibitor monotherapy is efficacious and safe compared to the 12-month maintenance of DAPT.P2Y 12 inhibitor monotherapy after short-term DAPT is associated with a lower incidence of major bleeding events without an increase in ischemic events, such as a composite of death, myocardial infarction, or stroke.This article discusses recent evidence of potent P2Y 12 inhibitor monotherapy after short-term DAPT, focusing on patients with ACS from randomized clinical trials and meta-analyses.
Sung‐Jin Hong (Mon,) conducted a review in Acute Coronary Syndrome. Short-term DAPT followed by P2Y12 inhibitor monotherapy vs. 12-month DAPT was evaluated. Short-term dual antiplatelet therapy for 1 to 3 months followed by potent P2Y12 inhibitor monotherapy reduces major bleeding without increasing ischemic events compared to 12-month DAPT in patients with acute coronary syndrome.